Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Treasury Shares (2016 - 2025)

Neurocrine Biosciences filings provide 15 years of Treasury Shares readings, the most recent being $2.6 million for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 8.33% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 8.33% increase, with the full-year FY2025 number at $2.6 million, up 8.33% from a year prior.
  • Treasury Shares hit $2.6 million in Q4 2025 for Neurocrine Biosciences, up from $1.5 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.6 million in Q4 2025 to a low of $500000.0 in Q4 2022.
  • Median Treasury Shares over the past 5 years was $1.8 million (2021), compared with a mean of $1.8 million.
  • Biggest five-year swings in Treasury Shares: crashed 75.0% in 2022 and later surged 380.0% in 2023.
  • Neurocrine Biosciences' Treasury Shares stood at $2.0 million in 2021, then crashed by 75.0% to $500000.0 in 2022, then surged by 380.0% to $2.4 million in 2023, then changed by 0.0% to $2.4 million in 2024, then increased by 8.33% to $2.6 million in 2025.
  • The last three reported values for Treasury Shares were $2.6 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025) per Business Quant data.